Development of new medicines for the growing population of patients living with respiratory diseases and allergies is becoming more challenging, but great opportunities exist to develop differentiated products and to move into new and expanding markets. That’s why we are committed to the advancement of respiratory research through biopharmaceutical development.
Chiltern has a team of respiratory and other medical professionals who understand the challenges of patients living with breathing disorders and who also recognize the seasonal aspects of patient recruitment. Working as a cross-functional group, the team collaborates with you to provide advice from medical, operational, regulatory and cost-efficiency perspectives. The relationships they foster with industry leaders and key professionals allow them to provide deeper insights and strategic guidance, leading to better patient experiences, improved clinical outcomes and expedited regulatory approvals.
Over the past five years, Chiltern has conducted 79 respiratory studies.
Top Respiratory Indications From the Past Five Years
- Allergic rhinitis
- Chronic obstructive pulmonary disease (COPD)
- Cystic fibrosis
- Idiopathic pulmonary fibrosis
- Non-cystic fibrosis bronchiectasis
- Pulmonary diseases
- Smoking cessation